RecruitingPhase 2NCT06043323
243
studies recruiting now
as of 7 Sept 2026
2,104
studies registered in total
as of 7 Sept 2026
14
countries with a recruiting site
as of 7 Sept 2026
8 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT06337318
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
RecruitingNot applicableNCT06832605
Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference
RecruitingPhase 2 / Phase 3NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingPhase 1 / Phase 2NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 243 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Follicular lymphoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Follicular lymphoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BCL2, HLA-DRB1, BCL6, IGH).
Treatments being studied
18 approved treatments and 60 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Lenalidomide (Lenalidomide accord)Approved: Lenalidomide Hydrochloride Monohydrate (Lenalidomide krka (previously lenalidomide krka d.d. novo mesto))Approved: Tazemetostat Hydrobromide (Tazverik)Approved: Mosunetuzumab (Lunsumio)Approved: UmbralisibApproved: Lisocabtagene MaraleucelApproved: CopanlisibApproved: Yttrium Y 90 Ibritumomab Tiuxetan (Zevalin)Approved: Duvelisib Monohydrate (Copiktra)Approved: Interferon Alfa-2b (Intron a)Approved: TazemetostatApproved: Umbralisib Tosylate (Ukoniq)Approved: Epcoritamab (Epkinly)Approved: OdronextamabApproved: Copanlisib Hydrochloride (Aliqopa)Approved: DuvelisibApproved: Obinutuzumab (Gazyvaro)Approved: Axicabtagene Ciloleucel (Yescarta)
Phase 3Doxorubicin (Adriblastina)
Phase 3Pixantrone
Phase 3Prednisone (Cortan)
Phase 3Fludarabine
Phase 3Tisagenlecleucel (Kymriah)
Phase 3Ibritumomab Tiuxetan
Phase 3Prednisolone (Cortalone)
Phase 3Vincristine Sulfate (Leurocristine sulfate)
+ 52 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).